State-of-the-art computing models and proprietary data generation are opening up new frontiers for TechBio companies.

Source thesis

Biological uncertainty and slow experimental feedback make drug discovery expensive and difficult to predict. The report discusses Link proprietary biological measurements, computational hypotheses and repeated wet-lab tests; Build single-cell disease atlases and tumor spatial models; Monetize through research partnerships, model access or an internally developed drug pipeline. Examples cited: Recursion, Relation, Noetik.